Oftan Metaoksedrin (Phenylephrine Hydrochloride)

Phenylephrine Hydrochloride, the active ingredient in Oftan Metaoksedrin, is a sympathomimetic (alpha‑1 adrenergic agonist) presented as an ophthalmic solution for ocular administration. It produces vasoconstriction of conjunctival vessels to reduce redness and induces pupil dilation, facilitating diagnostic procedures in ophthalmology. The product conforms to European Union pharmaceutical standards and is intended for use under professional supervision.

GNH USA supplies Oftan Metaoksedrin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing consistent quality, regulatory documentation and reliable logistics for global distribution.

Oftan Metaoksedrin (phenylephrine hydrochloride) is used in ophthalmology to manage conditions involving conjunctival vasodilation and to facilitate pupil dilation. - Ocular congestion: reduces redness by constricting conjunctival blood vessels. - Allergic conjunctivitis: alleviates redness and swelling associated with allergic eye reactions. - Pupil dilation (mydriasis): expands the pupil to improve visualization during diagnostic examinations.

Phenylephrine hydrochloride ophthalmic solution may cause local ocular reactions and, rarely, systemic effects.

Common Side Effects: - Transient eye irritation or burning sensation lasting a few minutes. - Mild conjunctival redness or hyperemia that resolves spontaneously. - Temporary blurred vision that improves as the drug effect wanes. - Mild headache reported by some patients after administration.

Serious or Rare Side Effects: - Significant increase in intra‑ocular pressure, especially in glaucoma patients. - Systemic hypertension or cardiovascular stimulation leading to palpitations. - Allergic contact dermatitis of the eyelid or peri‑ocular skin. - Severe ocular pain, corneal edema, or vision loss requiring immediate medical attention.

When using Oftan Metaoksedrin, certain precautions should be observed to ensure safety and effectiveness. - Avoid use in patients with narrow‑angle glaucoma: risk of increased intra‑ocular pressure. - Screen for cardiovascular disease: phenylephrine may raise systemic blood pressure. - Do not combine with other mydriatic agents without medical guidance: may cause excessive dilation. - Monitor for allergic reactions: discontinue if severe irritation or rash develops. - Use only as directed by an eye care professional: appropriate dosing and frequency are essential. - Store at room temperature: keep in original container, protect from light and moisture.

Phenylephrine hydrochloride can interact with certain systemic and ocular medications.

Major Interactions (Avoid): - Systemic sympathomimetics (e.g., pseudoephedrine): may cause additive hypertensive effects. - Monoamine oxidase inhibitors (MAOIs): increased risk of severe hypertension. - Other topical mydriatics (e.g., tropicamide): excessive pupil dilation and prolonged effect.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: may blunt intra‑ocular pressure‑lowering effect. - Antihypertensive agents: phenylephrine may reduce their efficacy, requiring blood pressure monitoring. - Topical corticosteroids: monitor for delayed wound healing when combined.